|
|
|
|
| LEADER |
01918nam a22004095i 4500 |
| 001 |
000282088 |
| 005 |
20211101082258.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2007 sz | s |||| 0|eng d |
| 020 |
|
|
|a 9783764377830
|
| 024 |
7 |
|
|a 10.1007/978-3-7643-7783-0
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Entry Inhibitors in HIV Therapy /
|c edited by Jacqueline D. Reeves, Cynthia A. Derdeyn.
|
| 250 |
|
|
|a 1st ed. 2007.
|
| 260 |
# |
# |
|a Basel :
|b Birkhäuser Basel :
|b Imprint: Birkhäuser,
|c 2007.
|
| 300 |
|
|
|a X, 206 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Milestones in Drug Therapy,
|
| 505 |
0 |
|
|a to entry inhibitors in the management of HIV infection -- The challenge of HIV sequence diversity in the envelope glycoprotein -- Attachment of human immunodeficiency virus to cells and its inhibition -- Inhibitors that target gp120-CD4 interactions -- Inhibitors that target gp120 interactions with coreceptor -- Inhibitors that target fusion -- HIV-1 entry inhibitors as microbicides -- Entry inhibition of HIV-1 subtype C isolates -- The utility of coreceptor typing in the clinic -- Future clinical prospects for entry inhibitors -- Enfuvirtide: from basic science to FDA approval -- Targets for drug development — past and present.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Virology.
|
| 650 |
|
0 |
|a Infectious diseases.
|
| 650 |
|
0 |
|a Pathology.
|
| 650 |
|
0 |
|a Cell biology.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Virology.
|
| 650 |
2 |
4 |
|a Infectious Diseases.
|
| 650 |
2 |
4 |
|a Pathology.
|
| 650 |
2 |
4 |
|a Cell Biology.
|
| 700 |
1 |
|
|a Reeves, Jacqueline D.
|e editor.
|
| 700 |
1 |
|
|a Derdeyn, Cynthia A.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|